Cardiac Toxicity clinical trials

Explore recruiting cardiac toxicity clinical trials.

Recruiting cardiac toxicity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiac Toxicity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Germany, France, Spain, Netherlands, Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"

Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)

Spain, Germany, Hungary, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study of [68Ga]Ga-ABY-025 PET for non-invasive quantification of HER2-status in solid tumors.

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Cardiac Toxicity trials by city

Cardiac Toxicity in Toronto Cardiac Toxicity in Vancouver Cardiac Toxicity in Montreal Cardiac Toxicity in Calgary Cardiac Toxicity in Edmonton Cardiac Toxicity in Ottawa Cardiac Toxicity in Winnipeg Cardiac Toxicity in Quebec City Cardiac Toxicity in Hamilton Cardiac Toxicity in Kitchener Cardiac Toxicity in London Cardiac Toxicity in Halifax Cardiac Toxicity in New York Cardiac Toxicity in Los Angeles Cardiac Toxicity in Chicago Cardiac Toxicity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease